{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T08:42:22Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094c6-e8cb-7fb3-a3c8-17302a3a25f6\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: ciprofibrate\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 re", "usd": 0.0, "recall": true }, "codex": { "seconds": 84.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094c6-e8d9-78e0-98a7-9726fbc01614\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: ciprofibrate\nRegistry id: vr.tr.ciprofibrate\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:56:07+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q3496452", "registryId": "vr.tr.ciprofibrate", "name": "ciprofibrate", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q3496452/", "model": { "registry_id": "vr.tr.ciprofibrate", "name": "ciprofibrate", "purpose": "Enable an agent to identify ciprofibrate, assess the condition and suitability of a material lot, and determine which handling or use decisions require additional evidence.", "definition": "Ciprofibrate is a synthetic chlorinated phenoxyisobutyric acid derivative of the fibrate class that modifies lipid metabolism primarily through activation of peroxisome proliferator-activated receptor alpha (PPARα).", "scope_statement": "This model owns ciprofibrate as the chemical substance registered as vr.tr.ciprofibrate in PHY / PHY.MAT, including identity, composition, material state, quality, biological activity and substance-specific constraints.", "in_scope": [ "Chemical identity and distinctions from related fibrates, salts and stereochemically specified substances", "Lot composition, assay, impurities and intended material grade", "Solid form, dissolution behaviour and condition-dependent physical properties", "Stability, storage history and analytical evidence supporting material disposition", "Pharmacological relationships, hazard evidence and jurisdiction-specific substance constraints" ], "out_of_scope": [ "Finished tablets, their excipients, packaging and product-specific shelf life", "Patient diagnosis, prescribing, dosing and treatment monitoring", "Manufacturing equipment and complete synthesis-process models", "Hyperlipidaemia and other disease models", "Independent models of other fibrates, metabolites or chemically distinct derivatives" ], "distinguishing_features": [ "Match the candidate to ciprofibrate's chemical structure and identifier record; PubChem identifies the parent record as CID 2763 with formula C13H14Cl2O3. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/2763)", "Require structure-sensitive analytical confirmation against an authenticated ciprofibrate reference; a fibrate label or molecular formula alone does not establish identity.", "Distinguish the parent substance from a salt, derivative or stereochemically specified material by recording the actual structure and the basis of the supplier's naming.", "Distinguish bulk ciprofibrate from a medicine containing it: the cited tablet product contains 100 mg ciprofibrate plus excipients. [Product SmPC](https://www.medicines.org.uk/emc/product/6650/smpc)" ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "Structure representation, molecular formula, verified CAS and EC identifiers where applicable, PubChem CID", "why_it_matters": "Prevents similarly named substances, related fibrates and derivative records from being merged." }, { "name": "Stereochemical specification", "kind": "category", "unit_or_values": "Unspecified, characterized mixture or explicitly characterized stereoisomer; analytical basis", "why_it_matters": "Prevents an unqualified registry name from silently becoming a claim about stereochemical composition." }, { "name": "Ciprofibrate assay", "kind": "measurement", "unit_or_values": "% mass fraction with as-is, dried or anhydrous basis and method", "why_it_matters": "Determines how much ciprofibrate a lot contains without confusing chromatographic area percentage with mass purity." }, { "name": "Related substances and residuals", "kind": "measurement", "unit_or_values": "% or mg/kg by analyte; method, reporting threshold and applicable limit", "why_it_matters": "Separates impurities, degradation products and process residuals from the intended active substance." }, { "name": "Solid form and phase", "kind": "state", "unit_or_values": "Observed phase; crystalline-form assignment where established; amorphous fraction, hydrate or solvate evidence", "why_it_matters": "Supports comparison of lots whose physical behaviour may differ despite matching chemical identity." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting range and thermal events in °C with method; boiling data only with pressure and evidence distinguishing decomposition", "why_it_matters": "Supports identity and handling assessment without inventing an experimentally unsupported boiling point." }, { "name": "Solubility and dissolution", "kind": "measurement", "unit_or_values": "mg/mL or mol/L; dissolution profile with solvent, pH, temperature, medium and solid form", "why_it_matters": "Determines whether a lot is suitable for analytical preparation or a downstream formulation process." }, { "name": "Material grade and disposition", "kind": "state", "unit_or_values": "Declared grade and specification; quarantined, released, rejected or awaiting retest", "why_it_matters": "Distinguishes research material, reference material and qualified pharmaceutical input." }, { "name": "Biological activity relationship", "kind": "relation", "unit_or_values": "Ciprofibrate to measured target, assay or lipid endpoint, with evidence and experimental context", "why_it_matters": "Preserves the distinction between chemical identity, demonstrated activity and clinical outcomes." }, { "name": "Applicable hazard and regulatory record", "kind": "relation", "unit_or_values": "SDS revision, classification system, jurisdiction, effective date and verified exposure limit if established", "why_it_matters": "Makes handling and permitted-use decisions depend on applicable evidence rather than a universal inferred classification." } ], "affordances": [ "Authenticate a candidate lot as ciprofibrate using identifier reconciliation and reference-based analytical evidence.", "Compare a lot's assay, impurity profile and physical properties with the specification required for its intended use.", "Select an evidenced sample-preparation or dissolution procedure for ciprofibrate material.", "Place degraded, unidentified or insufficiently documented material on hold pending investigation.", "Retrieve applicable handling controls and substance records for the relevant jurisdiction.", "Link qualified ciprofibrate material to downstream medicine or research models while preserving lot provenance." ], "agent_conduct": { "may": [ "Explain ciprofibrate as a fibrate lipid-lowering drug and where it is authorized, from official sources.", "Report warnings and interactions from official labelling." ], "must_not": [ "Recommend, dose or adjust ciprofibrate for a specific person.", "Advise combining it with other lipid-lowering drugs without a clinician.", "Advise obtaining it without a prescription where one is required.", "Present it as a substitute for diet or other prescribed treatment without evidence." ], "requires_human": [ "Starting, stopping or changing lipid-lowering treatment for a patient." ] }, "ethics": { "considerations": [ "Lipid-lowering drugs can cause muscle and liver harm, especially in combination.", "Patients with heart disease rely on accurate information." ], "affected_parties": [ "Patients with lipid disorders", "Prescribers and pharmacists", "Carers" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and pack details rather than by appearance alone." ], "failure_modes_and_hazards": [ "Muscle damage, especially with other lipid-lowering drugs.", "Liver effects.", "Interactions with anticoagulants." ], "what_it_is_for": [ "Ciprofibrate is encountered as a pharmaceutical active ingredient and in medicines used to manage certain blood lipid disorders.", "It is also encountered in pharmaceutical research and quality control, where material identity, purity and storage history inform suitability assessments." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology classifies ciprofibrate as C10AB08 within the fibrates." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q3496452: ciprofibrate", "url": "https://www.wikidata.org/wiki/Q3496452", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Ciprofibrate", "url": "https://en.wikipedia.org/wiki/Ciprofibrate", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "ciprofibrate-identity", "name": "Ciprofibrate identity", "description": "Establishes what substance the registry entry and each candidate material actually denote.", "rationale": "A fibrate-class name, supplier label or tablet name cannot independently establish ciprofibrate identity.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Reconciles the registry name with chemically explicit reference records.", "findings": [ { "id": "parent-substance-anchor", "name": "Parent substance anchor", "description": "Use the ciprofibrate parent record as an identity anchor; PubChem associates CID 2763 with C13H14Cl2O3. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/2763)", "questions": [ { "text": "Which verified structure and identifier records define ciprofibrate for vr.tr.ciprofibrate?", "kind": "definition", "id": "parent-substance-anchor-q01" }, { "text": "Do the supplier's CAS number and structure resolve to that same substance record?", "kind": "provenance", "id": "parent-substance-anchor-q02" } ] } ] }, { "id": "chemical-boundaries", "name": "Chemical boundaries", "description": "Separates identity-preserving descriptions from chemically distinct or more narrowly specified materials.", "findings": [ { "id": "parent-versus-specified-material", "name": "Parent versus specified material", "description": "Record evidence for stereochemistry, salts and derivatives without assuming that every ciprofibrate-labelled material has the same specification.", "questions": [ { "text": "Is the material the parent substance, a salt, a derivative or a stereochemically specified preparation?", "kind": "boundary", "id": "parent-versus-specified-material-q01" }, { "text": "What analytical evidence supports its stated stereochemical composition?", "kind": "measurement", "id": "parent-versus-specified-material-q02" } ] } ] } ] }, { "id": "ciprofibrate-lot-quality", "name": "Ciprofibrate lot quality", "description": "Captures the composition and qualification of actual ciprofibrate material.", "rationale": "Correct identity does not establish that a lot is sufficiently pure or qualified for pharmaceutical or research use.", "layers": [ { "id": "assay-and-impurities", "name": "Assay and impurities", "description": "Separates ciprofibrate content from related substances and residual materials.", "findings": [ { "id": "quantified-composition", "name": "Quantified composition", "description": "Require an assay basis and analyte-specific impurity evidence rather than a single unqualified purity percentage.", "questions": [ { "text": "What is the ciprofibrate mass assay, on which moisture basis, and with what uncertainty?", "kind": "measurement", "id": "quantified-composition-q01" }, { "text": "Which related substances, residual solvents and other relevant contaminants were tested, and against which limits?", "kind": "measurement", "id": "quantified-composition-q02" } ] } ] }, { "id": "grade-and-reference-traceability", "name": "Grade and reference traceability", "description": "Connects a lot's intended use to its specification and analytical references.", "findings": [ { "id": "qualified-material-status", "name": "Qualified material status", "description": "Research-grade material, an analytical reference and pharmaceutical input require separately evidenced qualification.", "questions": [ { "text": "Which specification and authenticated reference standard support this lot's identity and release results?", "kind": "provenance", "id": "qualified-material-status-q01" }, { "text": "Does the documented grade permit the proposed use, or must the material remain on hold?", "kind": "action", "id": "qualified-material-status-q02" } ] } ] } ] }, { "id": "ciprofibrate-physical-behaviour", "name": "Ciprofibrate physical behaviour", "description": "Describes the physical state and condition-dependent behaviour needed to prepare and assess ciprofibrate material.", "rationale": "Solution preparation and downstream performance require measured physical behaviour, not identity alone.", "layers": [ { "id": "solid-state-and-thermal-profile", "name": "Solid state and thermal profile", "description": "Records observed solid-state and thermal properties without presuming a particular polymorph catalogue.", "findings": [ { "id": "characterized-solid", "name": "Characterized solid", "description": "Attach physical-form assignments and thermal values to the tested ciprofibrate lot and measurement method.", "questions": [ { "text": "What diffraction, thermal or other evidence characterizes the ciprofibrate solid form?", "kind": "measurement", "id": "characterized-solid-q01" }, { "text": "What melting range or decomposition events were observed, under which test conditions?", "kind": "measurement", "id": "characterized-solid-q02" } ] } ] }, { "id": "solution-and-particle-behaviour", "name": "Solution and particle behaviour", "description": "Captures variables needed to reproduce dissolution and sample preparation.", "findings": [ { "id": "conditioned-dissolution-evidence", "name": "Conditioned dissolution evidence", "description": "Record solubility and dissolution separately, retaining medium, pH, temperature and material-form context.", "questions": [ { "text": "What equilibrium solubility is established for ciprofibrate in the proposed medium and at the intended pH and temperature?", "kind": "measurement", "id": "conditioned-dissolution-evidence-q01" }, { "text": "Which particle-size and solid-form observations are needed to reproduce the measured dissolution behaviour?", "kind": "measurement", "id": "conditioned-dissolution-evidence-q02" }, { "text": "Which validated preparation procedure achieves the required ciprofibrate concentration?", "kind": "action", "id": "conditioned-dissolution-evidence-q03" } ] } ] } ] }, { "id": "ciprofibrate-stability", "name": "Ciprofibrate stability", "description": "Connects storage and exposure history to evidence that the material remains suitable.", "rationale": "A finished tablet's storage instructions do not establish the stability of bulk ciprofibrate or its laboratory solutions.", "layers": [ { "id": "degradation-evidence", "name": "Degradation evidence", "description": "Records experimentally established chemical changes under relevant conditions.", "findings": [ { "id": "stability-indicating-assessment", "name": "Stability-indicating assessment", "description": "Use methods shown to distinguish ciprofibrate from relevant degradation products; do not infer degradation pathways from generic chemical expectations.", "questions": [ { "text": "Which temperature, humidity, light or solution conditions have actually been tested for ciprofibrate degradation?", "kind": "provenance", "id": "stability-indicating-assessment-q01" }, { "text": "Does the analytical method distinguish remaining ciprofibrate from the degradation products observed in those studies?", "kind": "measurement", "id": "stability-indicating-assessment-q02" } ] } ] }, { "id": "storage-and-retest", "name": "Storage and retest", "description": "Relates the material's history to justified storage and disposition decisions.", "findings": [ { "id": "lot-stability-disposition", "name": "Lot stability disposition", "description": "Base retest intervals and excursion decisions on evidence applicable to the bulk material, container or prepared solution.", "questions": [ { "text": "What container, storage conditions and retest interval are supported for this ciprofibrate lot?", "kind": "provenance", "id": "lot-stability-disposition-q01" }, { "text": "Following an excursion or prolonged solution storage, what testing is required before further use?", "kind": "action", "id": "lot-stability-disposition-q02" } ] } ] } ] }, { "id": "ciprofibrate-biological-interface", "name": "Ciprofibrate biological interface", "description": "Connects the substance to evidenced pharmacological effects and downstream clinical constraints.", "rationale": "Ciprofibrate's activity matters to material use, while prescribing and patient decisions belong in linked models.", "layers": [ { "id": "activity-and-endpoints", "name": "Activity and endpoints", "description": "Separates pharmacological classification, measured activity and clinical interpretation.", "findings": [ { "id": "fibrate-activity-context", "name": "Fibrate activity context", "description": "The cited SmPC classifies ciprofibrate as a fibrate and describes reductions in LDL and VLDL with increased HDL; these statements do not establish every proposed clinical benefit. [Product SmPC](https://www.medicines.org.uk/emc/product/6650/smpc)", "questions": [ { "text": "Which ciprofibrate-specific evidence supports each proposed molecular target or mechanism?", "kind": "provenance", "id": "fibrate-activity-context-q01" }, { "text": "Does a recorded result measure target activity, lipid changes or a clinical outcome?", "kind": "boundary", "id": "fibrate-activity-context-q02" } ] } ] }, { "id": "exposure-and-clinical-handoff", "name": "Exposure and clinical handoff", "description": "Preserves biological disposition and safety relationships needed by downstream models.", "findings": [ { "id": "clinical-constraint-links", "name": "Clinical constraint links", "description": "The cited SmPC reports prolonged elimination with renal impairment and muscle-related adverse effects including rhabdomyolysis; patient-level assessment belongs to the clinical model. [Product SmPC](https://www.medicines.org.uk/emc/product/6650/smpc)", "questions": [ { "text": "Which species, administration route and renal-function context apply to each recorded pharmacokinetic measurement?", "kind": "measurement", "id": "clinical-constraint-links-q01" }, { "text": "Which current product-specific contraindication and interaction records must a clinical model consult before considering ciprofibrate use?", "kind": "action", "id": "clinical-constraint-links-q02" } ] } ] } ] }, { "id": "ciprofibrate-handling-and-status", "name": "Ciprofibrate handling and status", "description": "Organizes the evidence needed for bulk-material handling and jurisdiction-specific use.", "rationale": "Therapeutic adverse effects, workplace hazard classifications and medicine authorizations answer different questions about ciprofibrate.", "layers": [ { "id": "bulk-material-hazards", "name": "Bulk material hazards", "description": "Records classifications and handling controls applicable to the actual material supplied.", "findings": [ { "id": "applicable-safety-evidence", "name": "Applicable safety evidence", "description": "Require a current, applicable SDS and supporting evidence; do not derive a GHS classification or occupational limit from therapeutic use.", "questions": [ { "text": "Which SDS revision and jurisdiction support the hazard classification assigned to this ciprofibrate material?", "kind": "provenance", "id": "applicable-safety-evidence-q01" }, { "text": "Is a ciprofibrate-specific occupational exposure limit established, and which authority issued it?", "kind": "provenance", "id": "applicable-safety-evidence-q02" }, { "text": "What controls does the applicable evidence require for weighing powder, spills and waste?", "kind": "action", "id": "applicable-safety-evidence-q03" } ] } ] }, { "id": "jurisdiction-and-product-boundary", "name": "Jurisdiction and product boundary", "description": "Separates substance identifiers and material requirements from authorization of particular medicines.", "findings": [ { "id": "permitted-use-evidence", "name": "Permitted-use evidence", "description": "Attach jurisdiction, date and scope to each regulatory claim; authorization of a ciprofibrate tablet does not qualify an arbitrary bulk lot.", "questions": [ { "text": "Which current substance or pharmaceutical-material requirements apply to the intended activity and jurisdiction?", "kind": "provenance", "id": "permitted-use-evidence-q01" }, { "text": "Does the cited record govern bulk ciprofibrate, a particular finished product or a supplier's qualification?", "kind": "boundary", "id": "permitted-use-evidence-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Verify identifiers and molecular properties against an authoritative chemical record before publication.", "Check current local product information for approved uses, contraindications and interactions; physical constants, purity specifications and chemical hazard classifications are not established here." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "ciprofibrate", "note": "Names the active substance rather than a particular medicinal product." }, { "scheme": "CAS Registry Number", "value_or_pattern": "52214-84-3", "note": "Identifier for ciprofibrate." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "C10AB08", "note": "Classifies ciprofibrate among fibrate lipid-modifying agents." }, { "scheme": "Molecular formula", "value_or_pattern": "C13H14Cl2O3", "note": "Describes elemental composition; it is not a unique structural identifier." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Used as an oral lipid-modifying medicine for selected forms of hypertriglyceridaemia and mixed dyslipidaemia.", "Used alongside dietary measures when those measures alone provide insufficient lipid control." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "289.16", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Can cause myopathy and, rarely, rhabdomyolysis; risk increases with certain interacting medicines, including statins.", "Renal impairment can increase drug exposure and muscle toxicity risk.", "Can cause elevations in liver enzymes and hepatic adverse effects.", "Can increase the risk of gallstone formation.", "Can potentiate coumarin anticoagulants and increase bleeding risk." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorisation, available formulations and approved indications vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Fibrates", "difference": "Fibrates are the broader drug class; ciprofibrate is one chemically defined member." }, { "name": "Fenofibrate", "difference": "Fenofibrate is a distinct fibrate administered as an ester prodrug of fenofibric acid; ciprofibrate is a different active acid." }, { "name": "Ciprofloxacin", "difference": "Ciprofloxacin is a fluoroquinolone antibacterial, whereas ciprofibrate is a lipid-modifying fibrate." }, { "name": "Ciprofibrate medicinal product", "difference": "A medicinal product contains a specified amount of ciprofibrate with excipients in a dosage form; the substance itself has no formulation or brand." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of ciprofibrate this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which CAS and EC identifiers are authoritative for the parent entry, and how should stereochemically specified ciprofibrate records relate to its scope?", "Which pharmacopoeial monographs or qualified specifications establish ciprofibrate assay methods, named impurities and acceptance limits?", "Which measured solid forms, melting ranges, pH-dependent solubilities and thermal-decomposition data are supported by primary experimental evidence?", "What bulk-material and solution stability evidence supports storage conditions, degradation-product identification and retest intervals?", "Which current SDS classifications, occupational exposure limits if any, and jurisdiction-specific material requirements apply to ciprofibrate?" ], "statistics": { "bundles": 7, "layers": 13, "findings": 19, "questions": 33 } }